Crossmark

Cardiovascular events in chronic myeloid leukemia clinical trials. Is it time to reassess and report the events according to cardiology guidelines?

Crossref DOI link: https://doi.org/10.1038/s41375-018-0247-1

Published Online: 2018-09-10

Published Print: 2018-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Aghel, Nazanin http://orcid.org/0000-0001-7137-9597
Delgado, Diego Hernan

Lipton, Jeffrey Howard
License Information

Text and Data Mining valid from 2018-09-10
More Information

Article History

Received: 10 June 2018

Revised: 29 July 2018

Accepted: 3 August 2018

First Online: 10 September 2018

Compliance with ethical standards

:

: DHD has received a grant from Novartis. JHL has received honoraria, been on the advisory boards, and has received research funding from Novartis, BMS, Pfizer, and Ariad. NA declares that she has no conflict of interest.